Literature DB >> 21731136

Sedative medication use: prevalence, risk factors, and associations with body mass index using population-level data.

Nicholas T Vozoris1, Richard S Leung.   

Abstract

STUDY
OBJECTIVES: To estimate the prevalence of and identify sociodemographic risk factors for sedative medication use in the general Canadian population, and to examine the association between sedative medication use and body mass index (BMI).
DESIGN: Cross-sectional study
SETTING: Canadian population PARTICIPANTS: Participants from the 1994-2003 Canadian national health surveys, the National Population Health Survey (NPHS) and the Canadian Community Health Survey (CCHS). For the 2003 CCHS, n = 134,072, ages 12-80+ years.
INTERVENTIONS: Not applicable MEASUREMENTS AND
RESULTS: The overall prevalence of sedative medication use in Canada in 2003 was 5.5%, having more than doubled since 1994. Notable rises in sedative medication use have occurred among men, non-elderly, and obese individuals. After adjusting for potential sociodemographic and health status confounders, including psychiatric comorbidities, the odds of sedative use were significantly greater among morbidly obese (BMI ≥ 35 kg/m(2)) men (OR = 1.89, 95%CI = 1.02-3.53) and underweight (BMI < 18.5 kg/m(2)) women (OR = 2.11, 95%CI = 1.26-3.53).
CONCLUSIONS: The use of sedative medications has substantially risen among the general Canadian population, and among particular population subgroups. The greater odds of sedative medication use found among morbidly obese men may reflect the presence of underlying obstructive sleep apnea, which may in turn serve to explain in part the known relationship between sedative medications and mortality. The increase in sedative medications coupled with their known adverse health associations raises potential public health concerns.

Entities:  

Keywords:  Sedative; body mass index; epidemiology

Mesh:

Substances:

Year:  2011        PMID: 21731136      PMCID: PMC3119828          DOI: 10.5665/SLEEP.1116

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  57 in total

1.  Comparing two different approaches to measuring drug use within the same survey.

Authors:  C I Neutel; W Walop
Journal:  Chronic Dis Can       Date:  2000

2.  Benzodiazepine use and wine consumption in the French elderly.

Authors:  R Lagnaoui; N Moore; J F Dartigues; A Fourrier; B Bégaud
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

3.  A prospective study of mortality among drug misusers during a 4-year period after seeking treatment.

Authors:  Michael Gossop; Duncan Stewart; Samantha Treacy; John Marsden
Journal:  Addiction       Date:  2002-01       Impact factor: 6.526

4.  Canadian community health survey--methodological overview.

Authors:  Yves Béland
Journal:  Health Rep       Date:  2002       Impact factor: 4.796

5.  Mortality associated with sleep duration and insomnia.

Authors:  Daniel F Kripke; Lawrence Garfinkel; Deborah L Wingard; Melville R Klauber; Matthew R Marler
Journal:  Arch Gen Psychiatry       Date:  2002-02

6.  Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada.

Authors:  K Tu; M M Mamdani; J E Hux; J B Tu
Journal:  J Am Geriatr Soc       Date:  2001-10       Impact factor: 5.562

7.  Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989.

Authors:  D K Wysowski; C Baum
Journal:  Arch Intern Med       Date:  1991-09

8.  Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian Study of Health and Aging.

Authors:  David B Hogan; Colleen J Maxwell; Tak S Fung; Erika M Ebly
Journal:  Can J Clin Pharmacol       Date:  2003

9.  Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom.

Authors:  Maurice M Ohayon; Malcolm H Lader
Journal:  J Clin Psychiatry       Date:  2002-09       Impact factor: 4.384

10.  Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery.

Authors:  William C Frey; John Pilcher
Journal:  Obes Surg       Date:  2003-10       Impact factor: 4.129

View more
  18 in total

1.  High dosage of hypnotics predicts subsequent sleep-related breathing disorders and is associated with worse outcomes for depression.

Authors:  Cheng-Ta Li; Ya-Mei Bai; Ying-Chiao Lee; Wei-Chung Mao; Mu-Hong Chen; Pei-Chi Tu; Ying-Sheue Chen; Tzeng-Ji Chen; Wen-Hang Chang; Tung-Ping Su
Journal:  Sleep       Date:  2014-04-01       Impact factor: 5.849

2.  Insomnia, hypnotic drug use, and patient well-being: first, do no harm.

Authors:  Barbara A Phillips
Journal:  Mayo Clin Proc       Date:  2012-05       Impact factor: 7.616

3.  Prescription Synthetic Oral Cannabinoid use Among Older Adults with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.

Authors:  Nicholas T Vozoris; Zhan Yao; Ping Li; Peter C Austin; Anne L Stephenson; Sudeep S Gill; Denis E O'Donnell; Andrea S Gershon; Paula A Rochon
Journal:  Drugs Aging       Date:  2019-11       Impact factor: 3.923

Review 4.  Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995.

Authors:  Yoko Murphy; Emily Wilson; Elliot M Goldner; Benedikt Fischer
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

5.  The need for pharmacovigilance in sleep medicine.

Authors:  Sairam Parthasarathy
Journal:  Sleep       Date:  2011-07-01       Impact factor: 5.849

6.  Over-the-counter and prescription sleep medication and incident stroke: the REasons for Geographic and Racial Differences in Stroke study.

Authors:  Megan E Petrov; Virginia J Howard; Dawn Kleindorfer; Michael A Grandner; Jennifer R Molano; George Howard
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-08-10       Impact factor: 2.136

7.  Zopiclone Increases the Arousal Threshold without Impairing Genioglossus Activity in Obstructive Sleep Apnea.

Authors:  Sophie G Carter; Michael S Berger; Jayne C Carberry; Lynne E Bilston; Jane E Butler; Benjamin K Y Tong; Rodrigo T Martins; Lauren P Fisher; David K McKenzie; Ronald R Grunstein; Danny J Eckert
Journal:  Sleep       Date:  2016-04-01       Impact factor: 5.849

8.  Eszopiclone and dexmedetomidine depress ventilation in obese rats with features of metabolic syndrome.

Authors:  William A Filbey; David T Sanford; Helen A Baghdoyan; Lauren G Koch; Steven L Britton; Ralph Lydic
Journal:  Sleep       Date:  2014-05-01       Impact factor: 5.849

9.  Insomnia Symptoms Are Not Associated with Dyslipidemia: A Population-Based Study.

Authors:  Nicholas T Vozoris
Journal:  Sleep       Date:  2016-03-01       Impact factor: 5.849

10.  Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study.

Authors:  Nicholas T Vozoris; Hadas D Fischer; Xuesong Wang; Geoffrey M Anderson; Chaim M Bell; Andrea S Gershon; Anne L Stephenson; Sudeep S Gill; Paula A Rochon
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.